Overview

A Study of LY2875358 in Japanese Participants With Advanced Cancer

Status:
Completed
Trial end date:
2014-08-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the safety and tolerability of LY2875358 in Japanese participants with cancer that is advanced and/or may have spread to another part of the body.
Phase:
Phase 1
Details
Lead Sponsor:
Eli Lilly and Company
Treatments:
Erlotinib Hydrochloride
Gefitinib